Abstract
A series of novel 1H- and 2H-indazole derivatives of the commercially available dehydroepiandrosterone acetate have been synthesized and tested for inhibition of human cytochrome 17alpha-hydroxylase-C(17,20)-lyase (CYP17), androgen receptor (AR) binding affinity, and cytotoxic potential against three prostate cancer (PC) cell lines.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Binding, Competitive / drug effects
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Dehydroepiandrosterone / analogs & derivatives*
-
Dehydroepiandrosterone / chemical synthesis*
-
Dehydroepiandrosterone / chemistry
-
Dehydroepiandrosterone / pharmacology*
-
Dehydroepiandrosterone / toxicity
-
Humans
-
Male
-
Prostatic Neoplasms / enzymology
-
Prostatic Neoplasms / pathology
-
Receptors, Androgen / metabolism
-
Steroid 17-alpha-Hydroxylase / antagonists & inhibitors*
-
Steroid 17-alpha-Hydroxylase / metabolism
Substances
-
Receptors, Androgen
-
Dehydroepiandrosterone
-
dehydroepiandrosterone acetate
-
Steroid 17-alpha-Hydroxylase